about
Body Mass Index Is Associated with Hypercholesterolemia following Thyroid Hormone Withdrawal in Thyroidectomized Patients.Glycemic Effectiveness of Metformin-Based Dual-Combination Therapies with Sulphonylurea, Pioglitazone, or DPP4-Inhibitor in Drug-Naïve Korean Type 2 Diabetic Patients.The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes.Risk of diabetes in patients treated with HMG-CoA reductase inhibitors.HMG CoA reductase inhibitor treatment induces dysglycemia in renal allograft recipients.Clinical efficacy of the novel thiazolidinedione lobeglitazone in patients with type 2 diabetes.Aromatase inhibitor use is a risk factor of carotid plaque presence in endocrine-responsive breast cancer patients.Statin therapy is associated with the development of new-onset diabetes after transplantation in liver recipients with high fasting plasma glucose levels.The association between skin auto-fluorescence of palmoplantar sites and microvascular complications in Asian patients with type 2 diabetes mellitus.Statin Use is Associated with Decreased Hepatocellular Carcinoma Recurrence in Liver Transplant PatientsPredictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 InhibitorsThe Effectiveness of Intermittent Fasting to Reduce Body Mass Index and Glucose Metabolism: A Systematic Review and Meta-AnalysisEffectiveness of Exercise Intervention in Reducing Body Weight and Glycosylated Hemoglobin Levels in Patients with Type 2 Diabetes Mellitus in Korea: A Systematic Review and Meta-AnalysisEfficacy and Safety of Gemigliptin in Post-Transplant Patients With Type 2 Diabetes MellitusNonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and DiagnosisGlucometabolic characteristics and higher vascular complication risk in Korean patients with type 2 diabetes with non-albumin proteinuria
P50
Q33998455-DC0C95EA-F975-46B2-95B3-2B786135254DQ37435728-6284BE26-636F-43F8-85E3-56097D6EA672Q42253478-399A4DB6-99F9-4263-B390-4975F53A2639Q48486361-50BF1619-17E7-460D-A568-448B3E9118CAQ48839479-61973CA2-A623-4ED3-8564-2D720B4D9E42Q49723177-054B6916-8575-43F8-9E65-F1FBF44365DDQ51256863-B9CCC25E-44A4-4CC3-A399-2E06A9A247F9Q51327702-9524C98A-A510-4C1F-A567-65622A9E5547Q52573376-89CD2756-65B9-4C21-97E6-584DD94B2759Q61799108-64AE921D-12EC-4BAC-A2CE-03A327B47303Q64230805-98B1D50F-6401-4BB8-A631-1B66F28FC567Q90633391-0B3D1849-F05A-4D78-9CD4-17793481BD5CQ90860427-0B950A6F-0762-4B9C-934A-D58D82A5BDDCQ91306274-A18148F9-80A7-4A69-9943-3BDC87E921EEQ91824073-097B6154-24F1-49F8-A2DC-998DDBB58182Q92449343-E18051CE-0444-45EF-8C8D-DF704AA1CE26
P50
description
investigador
@es
researcher
@en
name
Yongin Cho
@en
type
label
Yongin Cho
@en
prefLabel
Yongin Cho
@en
P31
P496
0000-0002-4645-816X